Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation

被引:100
作者
Yang, K [1 ]
Basu, A [1 ]
Wang, ML [1 ]
Chintala, R [1 ]
Hsieh, MC [1 ]
Liu, S [1 ]
Hua, J [1 ]
Zhang, ZF [1 ]
Zhou, J [1 ]
Li, M [1 ]
Phyu, H [1 ]
Petti, G [1 ]
Mendez, M [1 ]
Janjua, H [1 ]
Peng, P [1 ]
Longley, C [1 ]
Borowski, V [1 ]
Mehlig, M [1 ]
Filpula, D [1 ]
机构
[1] Enzon Pharmaceut, Piscataway, NJ 08854 USA
来源
PROTEIN ENGINEERING | 2003年 / 16卷 / 10期
关键词
Pichia; polyethylene glycol; therapeutic antibodies; TNF-alpha;
D O I
10.1093/protein/gzg093
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The utility of single-chain Fv proteins as therapeutic agents would be realized if the circulating lives of these minimal antigen-binding polypeptides could be both prolonged and adjustable. We have developed a general strategy for creating tailored monoPEGylated single-chain antibodies. Free cysteine residues were engineered in an anti-TNF-alpha scFv at the C-terminus or within the linker segments of both scFv orientations, V-L-linker-V-H and V-H-linker-V-L. High-level expression of 10 designed variant scFv proteins in Pichia pastoris allowed rapid purification. Optimization of site-specific conjugate preparation with 5, 20 and 40 kDa maleimide-PEG polymers was achieved and a comparison of the structural and functional properties of the scFv proteins and their PEGylated counterparts was performed. Peptide mapping and MALDI-TOF mass spectrometric analysis confirmed the unique attachment site for each PEG polymer. Indepen dent biochemical and bioactivity analyses, including binding affinities and kinetics, antigenicity, flow cytometric profiling and cell cytotoxicity rescue, demonstrated that the functional activities of the 10 designed scFv conjugates are maintained, while scFv activity variations between these alternative assays can be correlated with conjugate and analytical designs. Pharmacokinetic studies of the PEGylated scFv in mice demonstrated up to 100-fold prolongation of circulating lives, in a range comparable to clinical antibodies.
引用
收藏
页码:761 / 770
页数:10
相关论文
共 32 条
[1]  
[Anonymous], PROTEIN STRUCTURE PR
[2]   Rational design of a potent, long-lasting form of interferon:: A 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C [J].
Bailon, P ;
Palleroni, A ;
Schaffer, CA ;
Spence, CL ;
Fung, WJ ;
Porter, JE ;
Ehrlich, GK ;
Pan, W ;
Xu, ZX ;
Modi, MW ;
Farid, A ;
Berthold, W .
BIOCONJUGATE CHEMISTRY, 2001, 12 (02) :195-202
[3]   Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library [J].
Begent, RHJ ;
Verhaar, MJ ;
Chester, KA ;
Casey, JL ;
Green, AJ ;
Napier, MP ;
HopeStone, LD ;
Cushen, N ;
Keep, PA ;
Johnson, CJ ;
Hawkins, RE ;
Hilson, AJW ;
Robson, L .
NATURE MEDICINE, 1996, 2 (09) :979-984
[4]  
CARREY EA, 1989, PROTEIN STRUCTURE PR, P117
[5]   Therapeutic antibody fragments with prolonged in vivo half-lives [J].
Chapman, AP ;
Antoniw, P ;
Spitali, M ;
West, S ;
Stephens, S ;
King, DJ .
NATURE BIOTECHNOLOGY, 1999, 17 (08) :780-783
[6]   PEGylated antibodies and antibody fragments for improved therapy: a review [J].
Chapman, AP .
ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (04) :531-545
[7]   Long-acting growth hormones produced by conjugation with polyethylene glycol [J].
Clark, R ;
Olson, K ;
Fuh, G ;
Marian, M ;
Mortensen, D ;
Teshima, F ;
Chang, S ;
Chu, H ;
Mukku, V ;
CanovaDavis, E ;
Somer, T ;
Cronin, M ;
Winkler, M ;
Wells, JA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (36) :21969-21977
[8]   Antibody engineering [J].
Dall'Acqua, W ;
Carter, P .
CURRENT OPINION IN STRUCTURAL BIOLOGY, 1998, 8 (04) :443-450
[9]   Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library [J].
Feldhaus, MJ ;
Siegel, RW ;
Opresko, LK ;
Coleman, JR ;
Feldhaus, JMW ;
Yeung, YA ;
Cochran, JR ;
Heinzelman, P ;
Colby, D ;
Swers, J ;
Graff, C ;
Wiley, HS ;
Wittrup, KD .
NATURE BIOTECHNOLOGY, 2003, 21 (02) :163-170
[10]   Single-chain Fv designs for protein, cell and gene therapeutics [J].
Filpula, D ;
McGuire, J .
EXPERT OPINION ON THERAPEUTIC PATENTS, 1999, 9 (03) :231-245